AU6248798A - Treatment for premenstrual dysphoric disorder - Google Patents

Treatment for premenstrual dysphoric disorder

Info

Publication number
AU6248798A
AU6248798A AU62487/98A AU6248798A AU6248798A AU 6248798 A AU6248798 A AU 6248798A AU 62487/98 A AU62487/98 A AU 62487/98A AU 6248798 A AU6248798 A AU 6248798A AU 6248798 A AU6248798 A AU 6248798A
Authority
AU
Australia
Prior art keywords
treatment
dysphoric disorder
premenstrual dysphoric
premenstrual
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU62487/98A
Inventor
Louise R. Levine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU6248798A publication Critical patent/AU6248798A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU62487/98A 1997-01-29 1998-01-23 Treatment for premenstrual dysphoric disorder Abandoned AU6248798A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3617697P 1997-01-29 1997-01-29
US60036176 1997-01-29
PCT/US1998/001344 WO1998032436A1 (en) 1997-01-29 1998-01-23 Treatment for premenstrual dysphoric disorder

Publications (1)

Publication Number Publication Date
AU6248798A true AU6248798A (en) 1998-08-18

Family

ID=21887075

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62487/98A Abandoned AU6248798A (en) 1997-01-29 1998-01-23 Treatment for premenstrual dysphoric disorder

Country Status (5)

Country Link
EP (1) EP1014971A1 (en)
JP (1) JP2001511131A (en)
AU (1) AU6248798A (en)
CA (1) CA2275777A1 (en)
WO (1) WO1998032436A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2355982A (en) * 1999-11-03 2001-05-09 Lilly Co Eli Heterocyclic amino acids
KR100600550B1 (en) 2000-10-20 2006-07-13 에자이 가부시키가이샤 Nitrogenous aromatic ring compounds
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
WO2006030826A1 (en) 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. Medicinal composition
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd Method for assay on the effect of vascularization inhibitor
WO2007136103A1 (en) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
WO2008026748A1 (en) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
CN101600694A (en) 2007-01-29 2009-12-09 卫材R&D管理有限公司 Composition for treatment of undifferentiated-type of gastric cancer
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
US8735397B2 (en) * 2010-03-29 2014-05-27 Vanderbilt University Method for treating schizophrenia and related diseases
MX2012014776A (en) 2010-06-25 2013-01-29 Eisai R&D Man Co Ltd Antitumor agent using compounds having kinase inhibitory effect in combination.
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
EP2714937B1 (en) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
KR20150098605A (en) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 Amorphous form of quinoline derivative, and method for producing same
JP6411379B2 (en) 2013-05-14 2018-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
ES2926687T3 (en) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Highly pure quinoline derivative and method for its production
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL182285B1 (en) * 1994-08-12 2001-12-31 Lilly Co Eli Synthetic stimulating amino acids and methods of obtaining them
EP0776201B1 (en) * 1994-08-12 2001-10-17 Eli Lilly And Company Treating anxiety
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
TR199800877T2 (en) * 1995-11-16 1998-09-21 Eli Lilly And Company Stimulant amino acid derivatives.

Also Published As

Publication number Publication date
JP2001511131A (en) 2001-08-07
CA2275777A1 (en) 1998-07-30
EP1014971A4 (en) 2000-07-05
WO1998032436A1 (en) 1998-07-30
EP1014971A1 (en) 2000-07-05

Similar Documents

Publication Publication Date Title
AU5981098A (en) Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
AU6030199A (en) Medical tensioning system
AU6248798A (en) Treatment for premenstrual dysphoric disorder
AU9403798A (en) Human regulatory molecules
AU6562298A (en) Peptide-enhanced transfections
AU6785798A (en) Surgical retractor stay apparatus
AU8800598A (en) B7-binding molecules for treating immune diseases
GB9700899D0 (en) Novel treatment
AU1082299A (en) Manure treatment system
AU6249298A (en) Human anion channel
AU2587399A (en) Human transport-associated molecules
AU1893199A (en) Improved effluent treatment system
AU7759698A (en) Hair treatment agents
AU6966998A (en) Composition for treating pain
AUPO832597A0 (en) Wound treatment compositions
AU7247898A (en) Composition for treating pain
GB9608657D0 (en) Novel treatment
AU1234199A (en) Split end regenerating hair treatment agents
AU696976B2 (en) Effluent treatment
AU5330198A (en) Therapeutic compounds
AU5524399A (en) Inorgasmia treatment
GB2331514B (en) Effluent treatment
GB9721692D0 (en) Novel treatment
AUPO956097A0 (en) Treatment system
AU3984195A (en) Procedure for anticorrosive treatment